AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
No safety signals related to the vaccine candidate were identified
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Subscribe To Our Newsletter & Stay Updated